Lightnews — Scholar-powered news

CDC Recommends Twice-Yearly Lenacapavir for HIV Prevention

1 1

POZ Magazine @pozmagazine.bsky.social · 18d

On September 18, the CDC added twice-yearly lenacapavir (Yeztugo) to its recommendations for HIV pre-exposure prophylaxis. Health officials and advocates hope the CDC nod will increase insurers’ coverage of the new prevention tool.

www.poz.com/article/cdc-...

Advocates urge health insurers to ensure coverage of the highly effective new PrEP option.

ACTION ALERT: Watch “24 Hours to Save AIDS Research,” an Online Marathon to Highlight HIV Research Advances

Reposted by POZ Magazine

saveaidsresearch.bsky.social @saveaidsresearch.bsky.social · 24d

Join us on 24 Hours to Save AIDS Research NOW to hear about the incredible successes of the NIH-funded HIV research networks, with leaders Myron Cohen, Larry Corey, Joseph Eron, and Sharon Nachman on YouTube: bit.ly/45Qftts #saveAIDSresearch #HIV

5 6

POZ Magazine @pozmagazine.bsky.social · 25d

For the Sept. 16 marathon, global HIV experts will unite online to warn about massive federal budget cuts and help the public understand the benefits of HIV research. @avac.org

www.poz.com/article/acti...

Global HIV experts unite online to warn about massive federal budget cuts and help the public understand the benefits of HIV research.

Cuts Kill! — Kill the Cuts!

3 4

POZ Magazine @pozmagazine.bsky.social · Sep 9

Nearly 100 advocates held a rally on Capitol Hill on Friday, September 5, to protest pending cuts to HIV prevention, services and research in the United States and worldwide.

www.poz.com/article/cuts...

Advocates rally on Capitol Hill and lobby legislators to save HIV funding.

USCHA Day One: Scenes From the 2025 U.S. Conference on HIV/AIDS

POZ Magazine @pozmagazine.bsky.social · Sep 6

New: @trentstraube.bsky.social’s report on happenings so far at #USCHA #2025USCHA.

www.poz.com/article/usch...

Protests on Capitol Hill, DEI whiplash, dandelions and long-term survivors: Check them out at this year’s USCHA in Washington, DC.

1 1

POZ Magazine @pozmagazine.bsky.social · Sep 5

HIV funding rally at the Capitol. #CutsKill #SaveHIVfunding #2025USCHA #USCHA @prep4allnow.bsky.social @housingworksnyc.bsky.social @sfaidsfound.bsky.social @pozmagazine.bsky.social

4 1

POZ Magazine @pozmagazine.bsky.social · Sep 5

HIV funding rally at the Capitol. #CutsKill #SaveHIVfunding #2025USCHA #USCHA @prep4allnow.bsky.social @housingworksnyc.bsky.social @sfaidsfound.bsky.social

1 2

POZ Magazine @pozmagazine.bsky.social · Sep 4

The @pozmagazine.bsky.social team is ready to greet you at #2025USCHA!

HIV Maturation Inhibitor Shows Promise in Early Study

POZ Magazine @pozmagazine.bsky.social · Sep 3

News from #IAS2025: HRF-10071, a novel HIV maturation inhibitor, showed good antiviral activity in a small Phase II study. If confirmed in larger trials, it could offer a new option for people with drug-resistant virus & it may have potential for long-acting treatment.

www.poz.com/article/hiv-...

HRF-10071 substantially reduced viral load when tested as monotherapy, and trials of combination treatment are forthcoming.

CDC in Turmoil as Director Is Ousted, Top Leaders Resign

POZ Magazine @pozmagazine.bsky.social · Aug 28

Dr. Susan Monarez is out as director of the CDC after friction with Department of Health and Human Services head RFK Jr. At least three high-level agency officials resigned in protest, including Dr. Demetre Daskalakis, who previously led the nation’s HIV prevention efforts and mpox response.

CDC head Susan Monarez reportedly clashed with RFK Jr. over vaccine policy; Demetre Daskalakis issues blistering statement.

Cabenuva Can Be an Option for People Without Viral Suppression

Reposted by POZ Magazine

IAS - the International AIDS Society @iasociety.bsky.social · Aug 26

"Long-acting #HIV treatment with injectable cabotegravir & rilpivirine (Cabenuva) may be a good choice for people who have been unable to maintain viral suppression on daily oral therapy, according to a pair of studies presented at #IAS2025 in Rwanda" via @pozmagazine.bsky.social

Most people who started the long-acting injectables with a detectable viral load were able to bring their HIV under control.

Ulonivirine Shows Promise for Weekly Oral HIV Treatment

2 2

Reposted by POZ Magazine

IAS - the International AIDS Society @iasociety.bsky.social · Jul 31

"Ulonivirine, an experimental non-nucleoside reverse transcriptase inhibitor, has the potential to be a component of once-weekly oral #HIV treatment, according to Phase II study results presented at #IAS2025 in #Rwanda."

@lizhighleyman.bsky.social @pozmagazine.bsky.social

Study was halted early but the novel NNRTI is now being tested with a lower dose of islatravir.

Once-Monthly Oral PrEP Moves into Phase III Trials

5 12

POZ Magazine @pozmagazine.bsky.social · Jul 17

News from #IAS2025: An investigational once-monthly pill from Merck/MSD holds promise for HIV PrEP. With favorable pharmacokinetics & a good safety profile, MK-8527 could offer a long-acting HIV prevention option for people who don’t want injections.

www.poz.com/article/mont...

Merck’s MK-8527 could offer a long-acting HIV prevention option for people who don’t want injections.

Today I am 50. I'd be remiss if I didn't share the great news here. And here's why!

POZ Magazine @pozmagazine.bsky.social · Jul 17

Today I am 50. I'd be remiss if I didn't share the great news here. And here's why! #HIV www.poz.com/blog/50-nifty

I'm 50 and That's Nifty

Is DoxyPEP Spurring Antibiotic Resistance?

POZ Magazine @pozmagazine.bsky.social · Jul 16

As doxyPEP) becomes more widely used for prevention of STIs, questions remain about its implementation in the real world. At a symposium yesterday at #IAS2025, leading experts discussed outstanding challenges, including rising antibiotic resistance.

www.poz.com/article/doxy...

Drug-resistant gonorrhea is on the rise, but experts say benefits are worthwhile for those at high risk for sexually transmitted infections.

Momentum Builds For Long-Acting HIV Solutions

POZ Magazine @pozmagazine.bsky.social · Jul 14

#IAS2025: New WHO guidelines endorse lenacapavir PrEP, Medicines Patent Pool expands license for injectable cabotegravir for treatment & Merck’s once-monthly oral PrEP pill MK-8527 advances to Phase III trials.

www.poz.com/blog/momentu...

IAS 2025 spotlights scientific progress, funding challenges and leaders’ calls to action.

Experts at the 13th IAS Conference on HIV Science Warn Global HIV Gains at Risk Amid Sudden Funding Cuts

POZ Magazine @pozmagazine.bsky.social · Jul 8

Experts at the 13th IAS Conference on HIV Science Warn Global HIV Gains at Risk Amid Sudden Funding Cuts #IAS2025 #HIV www.poz.com/blog/experts...

Modelling and real-world data from Africa and Latin America revealing rising HIV acquisitions, stalled treatment and fragile health systems

Starting HIV Treatment Early Is Crucial for Your Health

3 4

POZ Magazine @pozmagazine.bsky.social · Jul 7

Today’s #HIV meds make living well with HIV more possible than ever. Here’s why starting treatment early matters. www.poz.com/article/star...

Today’s meds make living well with HIV more possible than ever. Here’s why starting treatment early matters.

NIH Ends Support for HIV Clinical Guidelines

POZ Magazine @pozmagazine.bsky.social · Jul 2

The National Institutes of Health intends to discontinue its support for federal HIV clinical guidelines by next summer, according to a memo from the NIH Office of AIDS Research. It is not yet clear whether maintenance of the guidelines will be taken over by another government agency.

U.S. federal guidelines have been the most comprehensive source for recommendations about HIV treatment and care.

Wistar Institute Unveils Center for HIV Cure Research

POZ Magazine @pozmagazine.bsky.social · Jun 19

Wistar Institute Unveils Center for HIV Cure Research -
The HIV Cure and Viral Disease Center brings together top scientists to advance #HIV cure research and study other viral diseases. www.poz.com/article/wist...

The HIV Cure and Viral Disease Center brings together top scientists to advance HIV cure research and study other viral diseases.

HIV, Queer Identity and the Politics of Health Care

POZ Magazine @pozmagazine.bsky.social · Jun 19

HIV, Queer Identity and the Politics of Health Care -
In today’s political climate, LGBTQ humanity is on the line. www.poz.com/article/hiv-...

In today’s political climate, LGBTQ humanity is on the line.

FDA Approves Twice-Yearly Lenacapavir for HIV Prevention

POZ Magazine @pozmagazine.bsky.social · Jun 19

The FDA approved twice-yearly lenacapavir (Yeztugo) for PrEP, making it the longest-acting HIV prevention method. Advocates lauded the eagerly awaited approval but expressed concern that the $28,000 annual price tag could limit access as HIV prevention funding is being slashed in the US & worldwide.

More than 99% of people who received Yeztugo in two large clinical trials remained HIV negative.

Are Cancer Rates Declining Among People With HIV?

5 9

POZ Magazine @pozmagazine.bsky.social · Jun 18

Rates of most types of cancer are falling or stable among people living with HIV, according to a large study. Cancers related to immune suppression continue to decline, but HIV-positive people remain at substantially higher risk for anal & liver cancer compared with the population at large.

Despite an overall decrease in cancer incidence, malignancies linked to human papillomavirus and viral hepatitis remain a concern.

The U.S. Government Is Starving Its Own Scientists of Knowledge

POZ Magazine @pozmagazine.bsky.social · Jun 18

The U.S. Government Is Starving Its Own Scientists of Knowledge: The National Agricultural Library canceled many journal subscriptions to save costs, leaving USDA staff without access. www.poz.com/article/us-g...

The National Agricultural Library canceled many journal subscriptions to save costs, leaving USDA staff without access.